Biogen Idec Looks To Develop PML Treatment
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.